Vedolizumab (Entyvio) in Crohn's disease
| Autor: | Cath Stansfield |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Advanced and Specialized Nursing
Crohn's disease medicine.medical_specialty Brand names business.industry medicine.disease Dermatology Inflammatory bowel disease digestive system diseases Vedolizumab 03 medical and health sciences Medical–Surgical Nursing 0302 clinical medicine medicine 030211 gastroenterology & hepatology 030212 general & internal medicine business medicine.drug |
| Zdroj: | Gastrointestinal Nursing. 19:20-28 |
| ISSN: | 2052-2835 1479-5248 |
| DOI: | 10.12968/gasn.2021.19.6.20 |
| Popis: | Vedolizumab is a biological medicine (biologic), marketed under the brand name Entyvio (Takeda), used to treat moderate-to-severe inflammatory bowel disease (IBD). This clinical review focuses primarily on the onset speed of vedolizumab in Crohn's disease. It consolidates research on the use of vedolizumab in IBD, including how the introduction of a formulation for subcutaneous injection has challenged IBD services to review the use of vedolizumab in Crohn's disease. It presents up-to-date information that addresses misconceptions among health professionals and patients that vedolizumab is slow to work in Crohn's disease. It explores why specialist IBD nurses might raise the availability of different biologics during patient consultations, as well as how to hold quality conversations on the topic and address potential patient misconceptions. Declaration of interest This article was commissioned and funded by Takeda UK Ltd, who suggested the author and topic. Takeda UK Ltd also reviewed and approved the content. Prescribing information for Entyvio can be found at the end of the article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|